Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer

Marta Crous-Bou, Miquel Porta, Tomàs López, Manuel Jariod, Núria Malats, Juan Alguacil, Eva Morales, Esteve Fernandez, Josep M. Corominas, Alfredo Carrato, Luisa Guarner, Francisco X. Real

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

24 Cites (Scopus)

Resum

OBJECTIVES: We analyzed the relation between mutations in codon 12 of the K-ras oncogene and lifetime consumption of tobacco in patients with exocrine pancreatic cancer (EPC). METHODS: Incident cases of EPC were prospectively identified and interviewed during hospital admission about smoking and other factors. Exact logistic regression was used to compare EPC cases (N = 107) with and without K-ras mutations (case-case study). RESULTS: Mutated cases were nonsignificantly less likely to have been smokers than wild-type cases: the odds ratio adjusted by age and sex was 0.54 (95% confidence interval, 0.10-2.69; P = 0.613). With respect to never smokers, adjusted odds ratios for former and current smokers were 0.79 and 0.36, respectively (P = 0.193). Pack-years smoked, years of smoking, and cigarettes smoked per year also tended to be higher in nonmutated than in mutated cases. Neither age at onset of smoking nor the time between quitting and diagnosis were associated with K-ras. CONCLUSIONS: Tobacco does not play a major part in the acquisition of K-ras mutations in the pancreatic epithelium. Although both smoking and K-ras mutations have important roles in the etiopathogenesis of EPC, the 2 processes may act independently. © 2007 Lippincott Williams & Wilkins, Inc.
Idioma originalAnglès
Pàgines (de-a)135-141
RevistaPancreas
Volum35
Número2
DOIs
Estat de la publicacióPublicada - 1 d’ag. 2007

Fingerprint

Navegar pels temes de recerca de 'Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer'. Junts formen un fingerprint únic.

Com citar-ho